Compounds and anti-tumor NQO1 substrates

US9611266B2 · kind B2 · utility

Assignees

• The Board of Trustees of the University of Illinois · US
• The Board of Regents of the University of Texas System · US

Inventors

• Paul J. Hergenrother · Champaign, US
• David Boothman · Dallas, US
• Joseph S. Bair · Albany, US
• Rahul Palchaudhuri · Cambridge, US
• Elizabeth I. Parkinson · Champaign, US

Key dates

• Filing date: Jan 11, 2016
• Grant date: Apr 4, 2017
• Expiry date: Jan 11, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/6561
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compounds are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.